{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:08:40Z","timestamp":1780654120084,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,4]]},"DOI":"10.1093\/ehjcvp\/pvae021","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T19:25:03Z","timestamp":1710357903000},"page":"171-172","source":"Crossref","is-referenced-by-count":1,"title":["Oral anticoagulants and antiplatelet treatment in different settings"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-6312","authenticated-orcid":false,"given":"Stefan","family":"Agewall","sequence":"first","affiliation":[{"name":"Editor-in-Chief"},{"name":"Institute of Clinical Sciences, Karolinska Institute of Danderyd , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"2026060505361914200_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ehjcvp\/pvad046","article-title":"The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide cohort study","volume":"9","author":"Halili","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/ehjcvp\/pvab060","article-title":"Rationale and design of the pragmatic clinical trial tREatment with beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)","volume":"8","author":"Rossello","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ehjcvp\/pvaa029","article-title":"Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction","volume":"7","author":"Joo","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ehjcvp\/pvaa018","article-title":"Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis","volume":"7","author":"Wilson","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026060505361914200_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvaa119","article-title":"Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26\u2009143 patients","volume":"8","author":"Hong","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026060505361914200_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ehjcvp\/pvac028","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA Registry","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvac022","article-title":"Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ehjcvp\/pvab043","article-title":"Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/eurheartj\/ehab785","article-title":"Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score","volume":"43","author":"Wurtz","year":"2022","journal-title":"Eur Heart J"},{"key":"2026060505361914200_bib12","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus Aspirin versus Aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026060505361914200_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/ehjcvp\/pvac023","article-title":"Long-term treatment with the combination of Rivaroxaban and Aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial","volume":"8","author":"Eikelboom","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ehjcvp\/pvac028","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA Registry","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvab050","article-title":"Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial","volume":"8","author":"Vanassche","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060505361914200_bib16","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1161\/STROKEAHA.116.014422","article-title":"Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study","volume":"47","author":"Bonde","year":"2016","journal-title":"Stroke"},{"key":"2026060505361914200_bib17","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026060505361914200_bib18","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1093\/ehjcvp\/pvac003","article-title":"Pharmapulse report-does the arrival of factor XI inhibitors mark the end of the NOAC era?","volume":"8","author":"Hasegawa","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae021\/57138090\/pvae021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/171\/58554066\/pvae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/171\/58554066\/pvae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:36:23Z","timestamp":1780652183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/3\/171\/7638940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,2]]},"published-print":{"date-parts":[[2024,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae021","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4]]}}}